

GRIFOLS

Grifols' national partnership with Habitat for Humanity International helps address affordable U.S. housing shortage

- *Through an expanded collaboration with the nonprofit, Grifols deepens its commitment to supporting an increase in accessible U.S. housing stock*
- *The 2022 State of the Nation's Housing report indicates a substantial rise in U.S. housing cost burdens for the first time in 10 years*
- *On International Volunteer Day, Grifols highlights its more than 15,000 volunteer hours dedicated to supporting the development of affordable housing in the U.S since 2014*

Barcelona, Spain, December 5, 2022 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today underscored its national partnership with housing nonprofit Habitat for Humanity International to continue supporting affordable housing in the United States.

The recently activated national alliance strengthens a relationship with Habitat that since 2014 has seen Grifols contribute nearly \$2 million and more than 15,000 volunteer hours to build and improve safe and decent homes in communities in states such as California, Colorado, North Carolina and Texas.

As a nationwide partner, Grifols now expands its support to even more Habitat organizations across the country, providing additional opportunities for Grifols employees to volunteer their time.

Partnerships that add to affordable housing stock take on greater importance given that the costs of U.S. homes continue to rise, with price appreciation reaching 20.6% in March 2022, marking the largest jump in 30 years of reporting.¹

“Grifols is proud to support Habitat’s mission of increasing affordability in the communities we call home,” said Vlasta Hakes, Grifols Senior Director of Corporate Affairs, noting that the work takes on added significance on International Volunteer Day. “We are excited to grow our partnership with Habitat on a national level in the U.S., expanding our employee volunteer efforts and financial contributions.”

¹ The State of the Nation's Housing 2022, Joint Center for Housing Studies of Harvard University

GRIFOLS

“At Habitat, we know that healthy communities and healthy housing help families thrive,” said Julie Laird Davis, Vice President, Corporate and Cause Marketing Partnerships, Habitat for Humanity International. “We are so grateful for Grifols’ expanded support this year to help even more families across the country become stronger and healthier through safe, decent and affordable housing.”

The Habitat for Humanity partnership is part of Grifols’ larger sustainability goals. Recognized as one of the most sustainable companies in the world, Grifols has developed its own 2030 Agenda, which is fully aligned with the United Nations Sustainable Development Goals. The company generates positive impact on the communities where its employees, donors and patients live through increasing support to social outreach initiatives, while also taking action across areas such as gender equality, talent development, the environment, product donations and a more sustainable supply chain.

To learn more about Grifols’ commitment to society, visit: [Impact on society | Grifols](#).

Media Contact:

Caleb Fernandez-Schendt
Corporate Communications
caleb.fernandezschendt@grifols.com
919-316-2128

Grifols Press Office
media@grifols.com
Tel. +34 93 571 00 02

Investor contact:

Investor Relations & Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com – sustainability@grifols.com
Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 400 across North America, Europe, Africa and the Middle East and China.

GRIFOLS

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 27,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.